Sentences with phrase «b cell vaccine»

Grant Title: 01787: Clinical advancement of RNA - transfected CD40 - B cell vaccine technology for cancer therapy

Therefore, we will continue to generate CD40 - B cell vaccines using freshly irradiated feeder cells.

Not exact matches

DPX - RSV is a small, B - cell epitope peptide vaccine targeting the unmet medical needs in respiratory syncytial virus (RSV).

But he added, «We need to improve the memory responses of T and B cells to make longer - lasting vaccines.»

Using the findings from this study, the team has designed vaccine immunogens to selectively trigger the cooperating antibody - producing B cells to cooperate to make broadly neutralizing antibodies in a manner that mimics broadly neutralizing antibody development in natural HIV infection.

When antigens such as viruses and vaccines enter the human body, germinal centers are produced within secondary lymph nodes and memory B cells are then induced from germinal - center B cells.

This group's achievement reverses the conventional wisdom that memory B cells are induced by high - affinity cells, possibly greatly influencing vaccine strategies targeting memory B cells.

«Mechanism for inducing memory B cell differentiation elucidated: Efficient induction of immune cells that remember antigens will lead to the development of new vaccines.»

Bach2, an important gene for inducing memory B cells, may become an important target in vaccine strategies.

To fend off HIV, researchers introduced one vaccine (ALVAC - HIV) to induce a T cell response — thereby alerting the immune system — and another (AIDSVAX B / E) later to spur an antibody response.

But in truth, most (26 of 28 vaccines currently licensed for human use) stimulate primarily a B - cell or antibody response, which in many cases is sufficient.

T cells and B cells reside there, and that's where you need to get the vaccine to get an immune response.

Thus, in principle, a successful vaccine has to stimulate the first B cells in this lineage and then coax them along a fairly narrow evolutionary path until they have changed enough to provide effective protection against HIV.

To create the individual vaccine, a receptor protein is extracted from the patient's malignant B cell lymphocytes and purified in large amounts.

To make the vaccine, researchers took a sample of a patient's tumors, which in this trial were made up of B cells (white blood cells that help the body battle disease and infection).

Understanding how to elicit memory B cells, along with plasmablasts, is critical for designing effective vaccines.

The new technique, pioneered by Wilson and fellow researchers at the Emory University School of Medicine in Atlanta, saves time by using antibodies produced by so - called B cells (white blood cells that produce and then ferry them to infection sites to battle invading germs) in response to vaccines instead of to actual infections.

Andy Heath of the University of Sheffield Medical School in the United Kingdom and colleagues have bypassed these problems by creating a vaccine that activates the B cells directly, without relying on T cells.

Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen Y - T, Hoffman EW, Ritter G, Old LJ, Gnjatic S. Vaccine - induced CD4 + T cell responses to MAGE - 3 protein in lung cancer patients.

Now as an Assistant Professor in Medicine at Harvard Medical School, Daniel uses membrane structure and function as a means to define B cell antigen recognition and inform vaccine design.

In vitro reconstitution of B cell receptor - antigen interactions to evaluate potential vaccine candidates.

When Georgia Tomaras of Duke University Medical Center opened this year's HIV Vaccines Keystone symposium last night, she said this is the first ever HIV Vaccines meeting that is held jointly with a meeting on B cell development and function.

«Research focused on basic B cell biology is the foundation for the development of an HIV vaccine designed to drive the B cell arm of the immune response.»

The late - boost study, led by scientists from AFRIMS and the Thai Ministry of Health, found that vaccine boosts containing AIDSVAX B / E generated increased, but short - lived, humoral and CD4 + T - cell responses that did not rise further after subsequent boosting.

As a postdoc, Taylor developed an innovative laboratory technique using metallic additives and magnets to test experimental vaccines to see which B cells bind to them.

Historically, many vaccines have been designed to evoke an antibody response by B cells following innoculation with weakened or dead pathogens.

The full paper that this statement is in response to can be found at: Niederberger et al. 2018 Safety and efficacy of immunotherapy with the recombinant B - cell epitope — based grass pollen vaccine BM32.

[13] AN1792 was an active vaccine, with Aβ aggregates as the antigen, and the meningoencephalitis is postulated to have been the result of the vaccine having roused a T - cell response against Aβ along with the necessary B - cell response, leading to a Th1 - biased inflammatory attack centralized on sites in the brain with local Aβ deposits.

«IL - 28B is a key regulator of B - and T - Cell vaccine responses against influenza» by Adrian Egli et al. published in PLOS Pathogens on Thursday 11 December 2014.

These include: 1) live viral vaccine neutralization by maternal Abs, 2) Ab feedback mechanisms, 3) elimination of vaccine - antigen / maternal Ab immune complexes by phagocytosis, 4) inhibition of B cell responses through epitope masking, and 5) inhibition of B cell responses by binding of IgG to the FcγRIIB (134, 135).

The study relates to a particular type of vaccine (killed) against a particular virus, influenza, though the findings might hold true for other killed vaccines and for those vaccines consisting only of proteins produced by GM in bacteria, yeast or insect cells, against diseases such as hepatitis B (HBV) and human papilloma virus (HPV, the causative agent of cervical cancer).

The trials would be for proof of concept, to show whether researchers can, for the first time in humans, stimulate the right B cells to start the process of making broadly neutralizing antibodies, long considered the «holy grail» of HIV vaccine research because they defend against infection by a broad spectrum of HIV strains.

Several companies and federal agencies have already contacted him about the influenza A and influenza B backbones, Kawaoka says, and he is hopeful the systems can be adopted by vaccine manufacturers and grown in cell culture facilities already available in the United States and Japan.

Differences in individuals» immune responses linked to flu vaccine effectiveness, the importance of resting phases in B cell development and research into whether pathogens cause type 1 diabetes.

Most current vaccines work by stimulating a class of white blood cells called B cells to make antibodies that circulate and control infections in the blood.

1994 saw her as Head of the Department of Transplantation Immunology at the CLB, in Amsterdam, and in 1999 she became Head of the department of the Immunology of the Laboratory of Vaccine Research of the National Institute of Public Health and Environmental Protection (RIVM), in Bilthoven, where her research activities focused on defining immunological correlates of protection on the T and B cell level after natural infection and vaccination.

Historically, many vaccines have been designed to evoke an antibody response by B cells following inoculation with weakened or dead pathogens.

A primary goal of vaccine development is to identify viral or bacterial epitopes that will elicit an immune response strong enough to establish a cadre of B and T cells that have «memory» to protect us when they encounter the real thing.

Idiotype / granulocyte - macrophage colony - stimulating factor fusion protein as a vaccine for b - cell lymphoma

When you introduce the vaccine into the body, it elicits an immune response and creates T - cells and B - cells.

Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, et al. (2011) CD40 - Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's Lymphoma.

Vaccines do the exact same thing but without causing the patient to suffer through the disease and stimulating the B - cells to produce the necessary antibodies and a memory of the disease or pathogen.

We have now improved the generation of this vaccine by generating canine specific feeder cells that are moderately more efficient at inducing canine B cells to grow from PBMCs.

In this study, we clinically tested a therapeutic platform that we have previously described in preclinical studies [12] in which B cells from NHL dogs are expanded in vitro using CD40L transfected K562 cells (KtCD40L) and then loaded with autologous tumor RNA to generate a cell - based vaccine.

These results suggest that tumor antigen loaded CD40 - B may serve as a practical alternative to DC in cell - based vaccine strategies for both dogs and humans with cancer.